Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Status:
Terminated
Trial end date:
2018-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether double-dose Ranibizumab are effective to
regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy
(PCV).